AI-Driven Precision Medicine: Comprehensive Applications in Disease Prediction, Personalized Treatment, and Drug Discovery

Kexin Yu[1], Jun Jiang[2], Zhigang Jiang[3], Jiangjiao Liu[4], Roy Rillera Marzo[5*]

[*]indicates the corresponding author.

Affiliations and emails:

[1] yukexin_zmu@163.com, First School of Clinical Medicine, Zunyi Medical University, Zunyi, China

[2] Jun_jiang@fudan.edu.cn, State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, School of Life Sciences, Fudan University, Shanghai, China

[3] 26323039@qq.com, Department of Statistics, School of Public Health, Zunyi Medical University, Xiaoyuan Road, Xinpu District, Zunyi City, Guizhou Province, China

[4] liujj_0123@qq.com, Heilongjiang provincial hospital

[5] rrmtexas@yahoo.com, Curtin University, Malaysia

Abstract

This review explores AI's transformative role in precision medicine, focusing on disease prediction, personalized treatment, and drug discovery. In disease prediction, AI uses EHRs, imaging, and multi-omics data to stratify risks: XGBoost outperforms traditional models in CVD risk prediction; deep learning enhances early cancer detection (e.g., oral cancer via histopathology images); multi-omics integration aids neurodegenerative disease forecasting; and GCNs predict infectious outbreaks via real-time keyword analysis. For personalized treatment, AI tailors strategies: it analyzes genomic profiles to guide cancer therapy (e.g., identifying HER2 activation in CDK4/6i-resistant breast cancer); PK/PD modeling optimizes drug dosages (e.g., rituximab in nephropathy); it refines clinical trial patient selection (e.g., ASM choice for epilepsy); improves mental health diagnosis/treatment; and designs personalized stroke rehabilitation via wearable sensor data. In drug discovery, AI accelerates the pipeline: it identifies targets (e.g., SSO binding sites in triple-negative breast cancer); virtual screening (e.g., DeepDock for JAK3 inhibitors) and de novo design (e.g., CLMs for PI3Kγ inhibitors) find lead compounds; MIFAM-DTI predicts drug-target interactions; AI optimizes clinical trial design; and it enables drug repurposing (e.g., identifying fibrosis-related drugs via EHRs). Key challenges include data privacy (addressed via blockchain/SecPri-BGMPOP), algorithmic bias (needing diverse datasets), explainable AI (critical for CDSS trust), and multi-omics integration. AI-driven precision medicine promises proactive, personalized healthcare, requiring collaboration across stakeholders for ethical implementation.

Key words: artificial intelligence；　disease prediction；　personalized treatment；　drug discovery

Introduction

Precision medicine, an approach to healthcare that tailors medical treatment to the individual characteristics of each patient, holds immense potential for revolutionizing disease management. By considering factors like genetics, lifestyle, and environment, precision medicine aims to deliver the right treatment to the right patient at the right time. Complementing this paradigm shift is the rapid advancement of artificial intelligence (AI) and machine learning (ML) techniques, which are increasingly being integrated into various aspects of healthcare. AI's ability to analyze vast datasets, identify patterns, and make predictions is proving invaluable in overcoming the limitations of traditional medical approaches. This literature review explores the transformative impact of AI on precision medicine, specifically focusing on its applications in disease prediction, personalized treatment strategies, and drug discovery.

This review will demonstrate how AI is revolutionizing precision medicine by enhancing disease prediction, personalizing treatment strategies, and accelerating drug discovery, ultimately leading to improved patient outcomes. To support this central argument, the review is structured into several key sections. First, we will examine AI's role in AI-Enhanced Disease Prediction and Risk Stratification, highlighting its capabilities in predicting cardiovascular disease risk, early cancer detection, forecasting neurodegenerative disease onset, and anticipating infectious disease outbreaks. This section will showcase how AI algorithms, leveraging electronic health records, medical imaging, and multi-omics data, can identify individuals at high risk, enabling proactive interventions. Second, the review will delve into AI-Powered Personalized Treatment Strategies, exploring AI-driven personalized cancer therapy, optimization of drug dosage, AI-assisted patient selection for clinical trials, personalized mental healthcare, and AI-enabled personalized rehabilitation programs. This section will illustrate how AI can tailor treatment plans based on individual patient profiles, maximizing therapeutic efficacy and minimizing adverse effects. Third, we will discuss AI's Role in Accelerating Drug Discovery and Development, focusing on AI-driven target identification, virtual screening for lead compounds, prediction of drug-target interactions, optimization of clinical trial design, and drug repurposing. This section will demonstrate how AI can expedite the drug development pipeline, reducing costs and time-to-market for novel therapies. Finally, the review will address the Challenges and Future Directions of AI in Precision Medicine, including data privacy concerns, algorithmic bias, the need for explainable AI, and the integration of multi-omics data. By addressing these challenges, we can pave the way for the ethical and effective implementation of AI in precision medicine, realizing its full potential to improve patient care.

AI-Enhanced Disease Prediction and Risk Stratification

The application of artificial intelligence (AI) and machine learning (ML) is revolutionizing disease prediction and risk stratification, offering unprecedented opportunities for proactive healthcare management. By harnessing the power of data analytics, AI algorithms can identify individuals at high risk for various diseases, enabling timely interventions and personalized prevention strategies.

Machine learning models are increasingly being applied to electronic health records (EHRs) to predict cardiovascular disease (CVD) risk, offering the potential for improved preventative healthcare strategies [1]. These models leverage the wealth of longitudinal data within EHRs, including demographics, medication history, lab results (lipids, glucose, renal function), and clinical measurements (blood pressure, BMI), to identify individuals at high risk of developing CVD [2]. For example, the eXtreme Gradient boosting (XGBoost) algorithm has demonstrated superior performance in ASCVD risk prediction compared to traditional Cox models, achieving a higher C-statistic [2]. Furthermore, risk models tailored to specific populations, incorporating time-variable information such as medication adherence, have shown improved accuracy over existing benchmark risk scores [3]. These advancements underscore the importance of considering genetic predispositions, lifestyle choices, and clinical markers as influential contributors to CVD development [1].

Beyond cardiovascular health, AI is transforming cancer detection through the analysis of medical im-

aging data, offering the potential for earlier and more accurate diagnoses [2, 5]. AI algorithms can learn from vast image datasets to automatically recognize, segment, and diagnose tumor lesions, improving efficiency and accuracy in imaging diagnosis [4]. Meta-analyses have revealed high sensitivity and specificity for AI models in detecting various cancers, such as lymphoma, suggesting their utility as diagnostic tools [5]. Deep learning architectures, particularly convolutional neural networks applied to histopathological images, have also demonstrated exceptional diagnostic performance in detecting oral potentially malignant disorders and oral cancer [6].

The predictive power of AI extends to neurodegenerative diseases, where it is being leveraged to analyze complex multi-omics data for early prediction and diagnosis [7]. The integration of genomics, proteomics, and metabolomics data, alongside neuroimaging and electronic health records, provides a comprehensive view of the patient. Deep learning methods can then exploit this information to identify multi-modal bio-markers that facilitate the development of personalized treatments, early diagnostic tools, and strategies for drug discovery and repurposing [7]. The integration of omics data with clinical parameters has been shown to improve the performance of AI models in diagnosis and risk stratification [8]. For instance, integrating metabolomic data with clinical scores has drastically improved the area under the curve in predicting non-malignant liver diseases [8]. This highlights the potential of multi-omics data, when combined with AI, to enhance the prediction of disease onset and progression, paving the way for more effective interventions in neurodegenerative conditions [8].

Finally, AI is proving to be a valuable tool for predicting infectious disease outbreaks and enhancing pandemic preparedness [9]. AI-driven surveillance can improve early warning systems for emerging infectious diseases by automatically filtering and updating search engine keywords in real-time [10]. Graph convolution network (GCN) models, for example, have been used to select search engine keywords automatically, successfully predicting daily case numbers and detecting early signals during outbreaks [10]. The integration of modern technologies, such as AI and big data analytics, enhances both active and passive surveillance efforts by improving the accuracy and speed of data collection, analysis, and reporting [11].

AI-Powered Personalized Treatment Strategies

The advent of artificial intelligence (AI) is revolutionizing healthcare, particularly in the development of personalized treatment strategies tailored to individual patient characteristics. This paradigm shift promises to enhance therapeutic efficacy and minimize adverse effects across a spectrum of diseases.

AI is increasingly instrumental in personalizing cancer therapy through the analysis of individual genomic and transcriptomic profiles [12]. By dissecting specific mutations, gene expression patterns, and other molecular signatures, AI algorithms can predict a patient's likely response to various treatments, guiding the selection of the most effective therapeutic approach [23, 28]. Zañudo et al., in a phase Ib/IIa trial involving exemestane plus everolimus and palbociclib for CDK4/6i-resistant metastatic breast cancer, demonstrated the power of multi-omics data in identifying resistance mechanisms, such as the convergent evolution of HER2 activation and BRAFV600E [12]. This suggests that comprehensive sequencing may identify patients most likely to benefit from CDK4/6i therapies. Similarly, Boucai et al. observed that exceptional responders to radioiodine (RAI) treatment for metastatic thyroid cancer exhibited lower MAPK transcriptional output and a higher thyroid differentiation score compared to non-responders, underscoring the potential of molecular profiling to predict RAI therapy response [13]. These findings illustrate the capacity of AI to refine cancer treatment decisions based on the unique molecular landscape of each patient.

Beyond oncology, AI-driven pharmacokinetic (PK) and pharmacodynamic (PD) modeling is emerging as a potent tool for optimizing drug dosage and treatment regimens [26, 45]. By analyzing extensive biological data, including genomics and proteomics, AI algorithms can predict drug release profiles, incorporate patient-specific factors, and optimize dosage regimens to achieve tailored and effective therapies [22, 26]. The work of Liang et al., who established a population PK/PD model for rituximab in primary membranous

nephropathy, exemplifies this approach. Their model demonstrated the potential to optimize dosing based on a monthly mini-dose, which showed comparable efficacy to standard dosages but with a significantly decreased cumulative dosage and safety risk [14]. Further illustrating this point, Chen et al. developed a PK model for teicoplanin in septic patients, revealing that standard doses may result in undertherapeutic concentrations and suggesting alternative dosing regimens to achieve optimal PK/PD parameters [15]. These examples highlight how AI can accelerate dosage optimization, reduce development costs, and improve treatment outcomes by predicting drug-target interactions, personalizing medicine approaches, and optimizing research and development processes [26, 45].

The application of AI extends to optimizing patient selection for clinical trials by predicting individual treatment responses [16]. Recognizing that individuals often respond differently to treatments than what is reported in clinical trials, AI offers a solution by analyzing large datasets and identifying subtle factors that may influence treatment outcomes [43, 44]. In the context of antiseizure medications (ASMs) for epilepsy, AI, particularly deep machine learning, holds promise for aiding in the individualized selection of the first and subsequent ASMs, potentially reducing the number of ineffective treatments a patient endures [17]. Likewise, in assisted reproductive technology (ART), AI has demonstrated potential for optimization and personalization of key steps, including drug selection and dosing, to improve the overall efficacy and safety of ART [18].

Personalized approaches are also being realized in mental healthcare, with AI playing a key role in improving diagnosis and treatment recommendations [19]. Machine learning and deep learning, subsets of AI, have demonstrated the ability to analyze mental health datasets and identify patterns associated with various mental health problems, which can improve treatment planning by predicting an individual's response to different interventions [19]. Predictive analytics, leveraging historical data to formulate preventative interventions, aligns with the move toward individualized and preventive mental healthcare [19].

Finally, AI is transforming stroke rehabilitation by enabling personalized programs tailored to individual patient needs [30, 38]. These programs leverage AI algorithms to analyze patient data, including medical history, imaging results, and sensor data from wearable devices, to design customized rehabilitation plans [20]. Interpretable machine learning frameworks can distinguish between the myoelectric patterns of stroke patients and healthy individuals, identifying potential gait impairments and providing reliable EMG biomarkers to manage post-stroke rehabilitation [21]. As Jyotismita Chaki et al. highlight, AI-based intelligent systems can assist post-stroke patients in rehabilitation, offering a more favorable approach compared to manual diagnosis [22].

AI's Role in Accelerating Drug Discovery and Development

AI is poised to revolutionize the pharmaceutical industry, particularly in accelerating drug discovery and development. Its capacity to process and analyze vast datasets, identify patterns, and generate novel insights is transforming traditional approaches, offering the potential to significantly reduce the time and cost associated with bringing new therapies to market.

AI is revolutionizing the initial stages of drug discovery by accelerating target identification and validation [23]. Traditional methods of identifying drug targets are often time-consuming and resource-intensive. AI algorithms, particularly those leveraging network biology and machine learning, can analyze vast biological networks to pinpoint key components involved in disease pathways, thus revealing potential therapeutic targets [24]. For example, AI can analyze multi-omics data (genomics, transcriptomics, proteomics) to identify genes or proteins that are significantly dysregulated in disease states [25]. Furthermore, AI can predict the structures of proteins to design drug molecules [26]. The power of AI in this domain is exemplified by the work of Fronk et al., who demonstrated the use of AI/ML to identify modulatory splice-switching oligonucleotide (SSO) binding sites on pre-mRNA, ultimately leading to the discovery of a novel target in triple-negative breast cancer [25]. These AI-designed SSOs decreased the proliferative and migratory behavior of TNBC cells, showcasing the potential of AI to extract actionable insights from RNA-seq data [25].

Building upon the identification of promising targets, AI-based virtual screening and de novo drug design are revolutionizing the process of lead compound discovery. Virtual screening employs computational algorithms to sift through vast libraries of chemical compounds, predicting their binding affinity and activity against a specific drug target [27]. This approach significantly accelerates the identification of potential drug candidates and reduces the reliance on traditional, time-consuming methods. The effectiveness of virtual screening is illustrated by Tajane et al.'s work, which utilized ligand-based virtual screening and molecular docking to identify a lead compound, N-(2, 4, 6-trimethylphenyl) phenanthridin-6-amine (MCULE-1492185963-0), with superior binding characteristics to silmitasertib, a known CK2 inhibitor, for cholangiocarcinoma treatment [27]. Similarly, Wei et al. employed a structure-based hybrid high-throughput virtual screening (HTVS) protocol combined with the DeepDock algorithm to identify novel JAK3 inhibitors [28]. They identified compound 8, demonstrating inhibitory potency against JAK3 and the MOLM-16 cell line, showcasing the potential of virtual screening to identify novel scaffolds [28]. De novo drug design, on the other hand, leverages AI to generate entirely new molecular structures with desired properties, effectively expanding the chemical space beyond known compounds. Moret et al. demonstrated the de novo design of phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using generative chemical language models (CLMs) [29]. Their approach involved creating a virtual compound library and refining it using a CLM-based classifier for bioactivity prediction, ultimately leading to the identification of a novel PI3Kγ ligand with sub-micromolar activity [29]. These AI-driven approaches not only accelerate the drug discovery process but also offer the potential to identify novel drug candidates with improved efficacy and reduced toxicity.

Beyond identifying and designing potential drug candidates, AI and machine learning are playing an increasingly vital role in predicting drug-target interactions (DTIs) and off-target effects, which are crucial for both drug discovery and drug repurposing [48, 50]. Several computational methods, like DTI-Voodoo, are being developed to combine molecular features and phenotypic effects of drugs with protein-protein interaction networks, using graph convolutional neural networks to predict DTIs [30]. The Multi-source Information Fusion and Attention Mechanism for Drug-Target Interaction (MIFAM-DTI) method exemplifies this approach, integrating multi-source information, including physicochemical properties and molecular fingerprints of drugs, along with dipeptide composition and Evolutionary Scale Modeling features of targets, to predict DTIs with improved accuracy [31]. These models often employ techniques like graph attention networks and multi-head self-attention to capture complex relationships within the data [31].

The application of AI extends to optimizing clinical trial design and patient recruitment, key bottlenecks in drug development [61, 63]. By analyzing vast datasets, including electronic health records and clinical trial data, AI can identify patient subgroups most likely to respond to a specific drug, improving patient selection and trial success rates [32]. This targeted approach not only accelerates the drug development process but also contributes to personalized medicine [32]. The integration of AI into in silico clinical trials can improve data analysis, modeling and simulation, personalized medicine approaches, trial design optimization, and virtual patient generation [33]. Vij et al. proposed the Drug Development based on Artificial Intelligence (DD-AI) framework, leveraging AI-driven algorithms and machine learning models to enhance the identification and optimization of drug candidates, predict clinical trial outcomes, and personalize patient treatment plans [34].

Finally, AI is significantly impacting drug repurposing, offering a cost-effective and efficient strategy to identify new therapeutic uses for existing drugs [66, 68, 69]. By leveraging machine learning (ML) and AI techniques on large datasets, researchers can accelerate the drug development process and reduce risks by computationally identifying potential drug repurposing candidates [35]. The work of Shakibfar et al., who utilized Danish electronic healthcare records (EHRs) and AI to identify drugs associated with altered risk of surgery related to intestinal fibrosis in Crohn's disease patients, showcases the potential of AI in addressing unmet medical needs [36]. AI's ability to integrate vast amounts of data, including gene expression, drug-target binding, and clinical information, allows for the prediction of therapeutic relationships, such as identifying existing drugs for cancer treatment [37]. Tanoli et al. emphasize the importance of comprehensive target activity profiles in systematically repurposing drugs by extending their target profiles to include potent off-targets

with therapeutic potential for new indications [35]. Furthermore, Challa et al. highlight the synergistic potential of combining machine learning techniques with the knowledge of scientific and clinical experts to balance human knowledge and machine intelligence for drug repurposing in rare diseases [38].

Challenges and Future Directions of AI in Precision Medicine

The transformative potential of artificial intelligence (AI) in precision medicine is undeniable, yet its successful implementation hinges on addressing several critical challenges. These challenges span ethical, technical, and practical considerations, demanding careful attention to data privacy, algorithmic fairness, explainability, and comprehensive data integration.

Addressing data privacy and security constitutes a foundational requirement for AI-driven healthcare. The sensitivity of patient data necessitates robust protection mechanisms to foster trust and ensure regulatory compliance [39]. Concerns regarding the privacy and security of electronic health records (EHRs) are prevalent among both patients and the public [39]. Moreover, healthcare professionals may exhibit insufficient awareness of potential data security risks [39]. Blockchain technology offers a promising avenue for establishing trusted and auditable computing environments, thereby empowering patients with greater control over their healthcare information [40]. Furthermore, advanced techniques like SecPri-BGMPOP, leveraging Boost Graph Convolutional Network Clustering (BGCNC), have been proposed to enhance security and privacy within cloud-based environments [41].

Beyond data security, mitigating bias and ensuring fairness in AI algorithms are paramount. AI systems have the potential to perpetuate and even exacerbate existing health disparities if not designed and evaluated with meticulous care [72, 74]. Biases can originate from diverse sources, including biased data, algorithmic design choices, and human decision-making processes [42]. For instance, if training data predominantly represents a specific demographic group, the resulting AI model may exhibit suboptimal performance when applied to underrepresented populations, potentially leading to inaccurate diagnoses or inappropriate treatment recommendations. Drukker et al. [43] highlighted five key stages in the medical imaging AI/ML pipeline where biases can be introduced: data collection, data preparation and annotation, model development, model evaluation, and model deployment. Overcoming these biases necessitates a multifaceted approach encompassing the use of diverse and representative datasets, the implementation of fairness-aware algorithms, and rigorous testing and validation across various patient subgroups [72, 74].

The integration of AI into Clinical Decision Support Systems (CDSSs) presents another significant hurdle: the "black box" nature of many AI algorithms. This opacity raises concerns regarding trust and transparency, thereby underscoring the critical need for Explainable AI (XAI) [44]. While AI-based CDSSs can effectively process vast amounts of data, the lack of transparency can compromise the reliability of their outputs [44]. This is particularly critical in high-stakes medical scenarios, such as emergency call centers where AI-powered CDSSs are employed to identify patients experiencing life-threatening cardiac arrest [45]. Amann et al. [45] emphasize that the value of explainability is contingent on factors such as technical feasibility, validation levels, context, the system's role in decision-making, and the key user groups. In this regard, Alabdulhafith et al. [46] provided model explanations to ensure efficiency, effectiveness, and trust in their developed model through local and global explanations.

Finally, realizing the full potential of AI-driven precision medicine requires the seamless integration of multi-omics data (genomics, transcriptomics, proteomics, metabolomics, etc.) with clinical information derived from electronic health records (EHRs) [47]. The exponential growth of omics data has spurred the development of numerous genetic databases, facilitating the clinical stratification of high-risk populations [48]. AI models are actively being developed to integrate this multi-modal biomedical data for data-driven knowledge discovery and causal inference, demonstrating promising results across a spectrum of biomedical and healthcare applications [47]. Health data analytics plays a crucial role in enabling precision medicine by harnessing diverse data sources, including genomic, clinical, and lifestyle information [49].

Conclusion

In summary, this review has highlighted the profound impact of AI on precision medicine across disease prediction, personalized treatment strategies, and accelerated drug discovery. AI algorithms are demonstrating remarkable capabilities in identifying high-risk individuals, tailoring therapies to individual patient profiles, and expediting the development of novel therapeutics. Addressing the challenges of data privacy, algorithmic bias, and the need for explainable AI is crucial for fostering trust and ensuring equitable access to the benefits of AI-driven precision medicine. The future of healthcare lies in the convergence of AI and precision medicine, promising a new era of proactive, personalized, and effective care. Realizing this vision requires sustained collaboration among researchers, clinicians, policymakers, and patients, coupled with a commitment to ethical considerations and continuous innovation. By embracing these principles, we can unlock the full potential of AI to transform healthcare and improve the lives of countless individuals, paving the way for a future where medicine is not just reactive but predictive, preventative, and precisely tailored to each unique patient.

Reference

[1] Dr. R. Deepa, Vijaya Bhaskar Sadu, P. C, Dr. A. Sivasamy, Early prediction of cardiovascular disease using machine learning: Unveiling risk factors from health records, AIP Advances, 2024.

[2] Chaiquan Li, Xiaofei Liu, P. Shen, Yexiang Sun, T. Zhou, Weiye Chen, Qi Chen, Hongbo Lin, Xun Tang, P. Gao, Improving cardiovascular risk prediction through machine learning modelling of irregularly repeated electronic health records, European Heart Journal. Digital Health, 2023, 5, 30 - 40.

[3] Fang He, John H Page, Jesisca Tandi, Abhijit Ghosh, C. Liman, J. Sarkar, K. Yeo, Major Adverse Cardiovascular Event Risk Prediction in Asian Patients After Myocardial Infarction: A Novel, Dynamic, Machine-learning Approach, Journal of Asian Pacific Society of Cardiology, 2023.

[4] Danxi Zheng, Xiujing He, Jing Jing, Overview of Artificial Intelligence in Breast Cancer Medical Imaging, Journal of Clinical Medicine, 2023, 12.

[5] A. Bai, M. Si, P. Xue, Yimin Qu, Yu Jiang, Artificial intelligence performance in detecting lymphoma from medical imaging: a systematic review and meta-analysis, BMC Medical Informatics and Decision Making, 2024, 24.

[6] R. K. Sahoo, K. Sahoo, G. Dash, Gunjan Kumar, Santos Kumar Baliarsingh, Bhuputra Panda, Sanghamitra Pati, Diagnostic performance of artificial intelligence in detecting oral potentially malignant disorders and oral cancer using medical diagnostic imaging: a systematic review and meta-analysis, Frontiers in Oral Health, 2024, 5.

[7] Andrea Termine, Carlo Fabrizio, C. Strafella, V. Caputo, L. Petrosini, C. Caltagirone, E. Giardina, R. Cascella, Multi-Layer Picture of Neurodegenerative Diseases: Lessons from the Use of Big Data through Artificial Intelligence, Journal of Personalized Medicine, 2021, 11.

[8] C. Baciu, Cherry Xu, Mouaid Alim, Khairunnadiya Prayitno, M. Bhat, Artificial intelligence applied to omics data in liver diseases: Enhancing clinical predictions, Frontiers in Artificial Intelligence, 2022, 5.

[9] Ania Syrowatka, Masha Kuznetsova, Ava Alsubai, Adam L. Beckman, P. Bain, K. Craig, Jianying Hu, G. Jackson, K. Rhee, D. Bates, Leveraging artificial intelligence for pandemic preparedness and response: a scoping review to identify key use cases, NPJ Digital Medicine, 2021, 4.

[10] Ligui Wang, Yuqi Liu, Hui Chen, S. Qiu, Yonghong Liu, Mingjuan Yang, X. Du, Zhenjun Li, Rongzhang Hao, Huaiyu Tian, Hongbin Song, Search-engine-based surveillance using artificial intelligence for early detection of coronavirus disease outbreak, Journal of Big Data, 2023, 10, 1-12.

[11] Backyard flock sampling and artificial intelligence: A dual strategy for early detection of Avian Influenza and Newcastle Disease, German Journal of Veterinary Research, 2024.

[12] Jorge Gómez Tejeda Zañudo, R. Barroso-Sousa, Esha Jain, Qing Jin, Tianyu Li, Jorge E. Buendia-Buendia, A. Pereslete, Daniel L. Abravanel, Arlindo R Ferreira, E. Wrabel, K. Helvie, Melissa E

Hughes, Ann H. Partridge, Beth Overmoyer, N. Lin, N. Tayob, S. Tolaney, N. Wagle, Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial, Nature Communications, 2024, 15.

[13] Laura Boucai, Mahesh Saqcena, F. Kuo, R. Grewal, N. Socci, J. Knauf, Gnana P. Krishnamoorthy, Mabel Ryder, A. Ho, R. Ghossein, L. Morris, V. Seshan, J. Fagin, Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy., Clinical cancer research : an official journal of the American Association for Cancer Research, 2023.

[14] Hao Liang, Zhenling Deng, Shu Niu, Weijie Kong, Yang Liu, Song Wang, Haiyan Li, Yue Wang, Danxia Zheng, Dongyang Liu, Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study, Frontiers in Pharmacology, 2024, 15.

[15] Chao-Yang Chen, M. Xie, J. Gong, Ning Yu, Ran Wei, Lili Lei, Siru Zhao, Ruoming Li, Xiu Dong, Xiang-lin Zhang, Ying Zhou, Shuangling Li, Yi-min Cui, Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis, Frontiers in Pharmacology, 2023, 14.

[16] Claudio Carini, A. Seyhan, Tribulations and future opportunities for artificial intelligence in precision medicine, Journal of Translational Medicine, 2024, 22.

[17] Charlene L. Gunasekera, J. Sirven, A. Feyissa, The evolution of antiseizure medication therapy selection in adults: Is artificial intelligence -assisted antiseizure medication selection ready for prime time?, Journal of Central Nervous System Disease, 2023, 15.

[18] S. Hanassab, A. Abbara, Arthur C. Yeung, M. Voliotis, K. Tsaneva-Atanasova, T. Kelsey, Geoffrey H. Trew, Scott M. Nelson, T. Heinis, W. Dhillo, The prospect of artificial intelligence to personalize assisted reproductive technology, NPJ Digital Medicine, 2024, 7.

[19] A. Alhuwaydi, Exploring the Role of Artificial Intelligence in Mental Healthcare: Current Trends and Future Directions – A Narrative Review for a Comprehensive Insight, Risk Management and Healthcare Policy, 2024, 17, 1339 - 1348.

[20] Bin Wu, Real Time Monitoring Research on Rehabilitation Effect of Artificial Intelligence Wearable Equipment on Track and Field Athletes, EAI Endorsed Trans. Pervasive Health Technol., 2024, 10.

[21] Iqram Hussain, Rafsan Jany, Interpreting Stroke-Impaired Electromyography Patterns through Explainable Artificial Intelligence, Sensors (Basel, Switzerland), 2024, 24.

[22] Jyotismita Chaki, Marcin Wo niak, Deep Learning and Artificial Intelligence in Action (2019–2023): A Review on Brain Stroke Detection, Diagnosis, and Intelligent Post-Stroke Rehabilitation Management, IEEE Access, 2024, 12, 52161-52181.

[23] Purnendu B. Acharjee1, Bhupaesh Ghai, Muniyandy Elangovan, S. Bhuvaneshwari, Ravi Rastogi, P. Rajkumar, Exploring AI-driven approaches to drug discovery and development, The Scientific Temper, 2023.

[24] Yujie You, Xin Lai, Ying Pan, Huiru Zheng, J. Vera, Suran Liu, Senyi Deng, Le Zhang, Artificial intelligence in cancer target identification and drug discovery, Signal Transduction and Targeted Therapy, 2022, 7.

[25] Alyssa D Fronk, M. Manzanares, P. Zheng, Adam Geier, K. Anderson, Shaleigh Stanton, Hasan Zumrut, Sakshi Gera, Robin Munch, Vanessa Frederick, Priyanka Dhingra, G. Arun, Martin Akerman, Development and validation of AI/ML derived splice-switching oligonucleotides, Molecular Systems Biology, 2024, 20, 676 - 701.

[26] Mohammad Ali Mahjoub, Zahra Sheikholislam, Artificial Intelligence in Drug Discovery and Delivery: Advancements and Applications, Journal of Biomedical Research & Environmental Sciences, 2023.

[27] Pravin Tajane, N. Kayande, Avinash Bhosale, Sumit Deore, Harshal Tare, Design and Discovery of Silmitasertib-based Drugs as a Potential Casein Kinase II Inhibitor for Cholangiocarcinoma

through Hybrid In-silico Ligand-Based Virtual Screening with Molecular Docking Method, INTER-NATIONAL JOURNAL OF DRUG DELIVERY TECHNOLOGY, 2023.

[28] Juying Wei, Youlu Pan, Zheyuan Shen, Liteng Shen, Lei Xu, Wenjuan Yu, Wenhai Huang, A hybrid energy-based and AI-based screening approach for the discovery of novel inhibitors of JAK3, Frontiers in Medicine, 2023, 10.

[29] Michael Moret, Irene Pachon Angona, Leandro Cotos, Shen Yan, Kenneth Atz, Cyrill Brunner, M. Baumgartner, F. Grisoni, G. Schneider, Leveraging molecular structure and bioactivity with chemical language models for de novo drug design, Nature Communications, 2023, 14.

[30] Tilman Hinnerichs, R. Hoehndorf, DTI-Voodoo: machine learning over interaction networks and ontology-based background knowledge predicts drug–target interactions, Bioinformatics, 2021, 37, 4835 - 4843.

[31] Jianwei Li, Lianwei Sun, Lingbo Liu, Ziyu Li, MIFAM-DTI: a drug-target interactions predicting model based on multi-source information fusion and attention mechanism, Frontiers in Genetics, 2024, 15.

[32] Omega John Unogwu, Mabel Ike, Opkanachi Omatule Joktan, Employing Artificial Intelligence Methods in Drug Development: A New Era in Medicine, Mesopotamian Journal of Artificial Intelligence in Healthcare, 2023.

[33] Emmanuel Chamorey, Jocelyn Gal, B. Mograbi, Gerard Milano, Critical Appraisal and Future Challenges of Artificial Intelligence and Anticancer Drug Development, Pharmaceuticals, 2024, 17.

[34] Priya Vij, Pharma in The Digital Era: The Role of Artificial Intelligence in Drug Development, Communications on Applied Nonlinear Analysis, 2024.

[35] Ziaurrehman Tanoli, M. Vähä-Koskela, T. Aittokallio, Artificial intelligence, machine learning, and drug repurposing in cancer, Expert Opinion on Drug Discovery, 2021, 16, 977 - 989.

[36] Saeed Shakibfar, K. Allin, Tine Jess, Maria Antonietta Barbieri, V. Battini, Eva Simoncic, J. Kirchgesner, Trond Ulven, Maurizio Sessa, Drug Repurposing in Crohn's Disease Using Danish Real-World Data, Pragmatic and Observational Research, 2024, 15, 17 - 29.

[37] Na Ly Tran, Hyerim Kim, Cheol-Hee Shin, Eun Ko, Seung Ja Oh, Artificial intelligence-driven new drug discovery targeting serine/threonine kinase 33 for cancer treatment, Cancer Cell International, 2023, 23.

[38] A. Challa, Nicole M. Zaleski, Rebecca N. Jerome, R. Lavieri, J. Shirey-Rice, A. Barnado, C. Lindsell, D. Aronoff, L. Crofford, Raymond C. Harris, T. Alp Ikizler, I. Mayer, K. Holroyd, J. Pulley, Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases, Frontiers in Genetics, 2021, 12.

[39] Faiza Tazi, A. Nandakumar, J. Dykstra, Prashanth Rajivan, Sanchari Das, SoK: Analyzing Privacy and Security of Healthcare Data from the User Perspective, ACM Transactions on Computing for Healthcare, 2024, 5, 1 - 31.

[40] Preeti Rani, Sonia Verma, S. Yadav, Bipin Kumar Rai, Mahaveer Singh Naruka, Devendra Kumar, Simulation of the Lightweight Blockchain Technique Based on Privacy and Security for Healthcare Data for the Cloud System, Int. J. E Health Medical Commun., 2022, 13, 1-15.

[41] Moorthi Kuttiyappan, Jothi Prabha Appadurai, B. P. Kavin, Jeeva Selvaraj, Hong-Seng Gan, Wen-Cheng Lai, Big Data Privacy Protection and Security Provisions of the Healthcare SecPri-BGM-POP Method in a Cloud Environment, Mathematics, 2024.

[42] Emilio Ferrara, Fairness And Bias in Artificial Intelligence: A Brief Survey of Sources, Impacts, And Mitigation Strategies, ArXiv, 2023, abs/2304.07683.

[43] K. Drukker, Weijie Chen, Judy Gichoya, Nicholas P. Gruszauskas, Jayashree Kalpathy-Cramer, Sanmi Koyejo, Kyle Myers, Rui C. Sá, B. Sahiner, Heather M. Whitney, Zi Zhang, M. Giger, Toward fairness in artificial intelligence for medical image analysis: identification and mitigation of potential biases in the roadmap from data collection to model deployment, Journal of Medical Imaging, 2023, 10.

[44] Se Young Kim, Daeho Kim, Min Ji Kim, Hyo Jin Ko, O. Jeong, XAI-Based Clinical Decision Support Systems: A Systematic Review, Applied Sciences, 2024.

[45] J. Amann, Dennis Vetter, S. Blomberg, H. Christensen, M. Coffee, S. Gerke, T. Gilbert, Thilo Hagendorff, Sune Holm, Michelle Livne, Andy Spezzatti, Inga Strümke, R. Zicari, V. Madai, To explain or not to explain?—Artificial intelligence explainability in clinical decision support systems, PLOS Digital Health, 2022, 1.

[46] Maali Alabdulhafith, Hager Saleh, H. Elmannai, Zainab H. Ali, Shaker El-Sappagh, Jong-Wan Hu, Nora El-Rashidy, A Clinical Decision Support System for Edge/Cloud ICU Readmission Model Based on Particle Swarm Optimization, Ensemble Machine Learning, and Explainable Artificial Intelligence, IEEE Access, 2023, 11, 100604-100621.

[47] L. Tong, Wenqi Shi, Monica Isgut, Yishan Zhong, Peter Lais, L. Gloster, Jimin Sun, Aniketh Swain, F. Giuste, May D. Wang, Integrating Multi-Omics Data With EHR for Precision Medicine Using Advanced Artificial Intelligence, IEEE Reviews in Biomedical Engineering, 2023, 17, 80-97.

[48] Mahaly Baptiste, Sarah Shireen Moinuddeen, Courtney Lace Soliz, Hashimul Ehsan, G. Kaneko, Making Sense of Genetic Information: The Promising Evolution of Clinical Stratification and Precision Oncology Using Machine Learning, Genes, 2021, 12.

[49] Vyvyenne Michelle Chigboh, Stephane Jean Christophe Zouo, Jeremiah Olamijuwon, Health data analytics for precision medicine: A review of current practices and future directions, International Medical Science Research Journal, 2024.